logo
logo
SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates
Every plan includes:
✓Signal-Driven Leads Based on YOUR ICP
✓Slack + Chrome real-time alerts
✓No duplicates — only new events
INDUSTRY FIRST

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

Jan 25, 2024•over 1 year ago

Amount Raised

$23.9 Million

MorrisvilleBiotechnology

Investors

Biomedical Advanced Research And Development Authority (Barda)

Description

Locus Biosciences announced the release of $23.9 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the first phase 2 trial of CRISPR-engineered bacteriophage therapy for treating urinary tract infections (UTIs) caused by drug-resistant E. coli.

Company Information

Company

Locus Biosciences

Location

Morrisville, North Carolina, United States

About

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

Company News

(10 articles)
Thu, 17 Jul 2025 07:00:00 GMT

The good virus – phage therapeutics - IQVIA

Thu, 03 Jan 2019 08:00:00 GMT

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics - PR Newswire

Wed, 18 May 2022 07:00:00 GMT

J&J-backed Locus closes $35M financing to push CRISPR-based antibacterial drug into phase 2/3 - fiercebiotech.com

Thu, 19 Mar 2020 07:00:00 GMT

World's-first clinical trial for a CRISPR-Cas3 phage therapy. Interview: Joseph Nixon, Locus Biosciences. - CRISPR Medicine News

Mon, 09 Sep 2024 07:00:00 GMT

Phage Therapy’s Neglected Potential Is Finally Being Realized - Genetic Engineering and Biotechnology News

Fri, 25 Feb 2022 08:00:00 GMT

Why Locus Biosciences Built A Bacteriophage Factory - Bioprocess Online

Tue, 22 Mar 2022 07:00:00 GMT

Locus’ Pac-Man-Like Precision Medicine Could Negate Antibiotic Collateral Damage - BioSpace

Fri, 13 Sep 2024 07:00:00 GMT

Future of CRISPR: Gene Editing Technologies Herald Landmark Clinical Trials - Infectious Disease Advisor

Thu, 20 Jun 2024 07:00:00 GMT

CRISPR technology’s next wave: Eight companies to watch in 2024 - Labiotech.eu

Tue, 17 Jul 2018 07:00:00 GMT

Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - PR Newswire

FundzWatch™ Score

66
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech